REGN
Regeneron Pharmaceuticals Inc
NASDAQ: REGN · HEALTHCARE · BIOTECHNOLOGY
$707.06
+3.02% today
Updated 2026-04-30
Market cap
$74.13B
P/E ratio
17.27
P/S ratio
4.97x
EPS (TTM)
$40.94
Dividend yield
0.52%
52W range
$475 – $820
Volume
0.7M
Regeneron Pharmaceuticals Inc (REGN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.45M | $125.02M | $238.46M | $379.27M | $459.07M | $445.82M | $1.38B | $2.10B | $2.82B | $4.10B | $4.86B | $5.87B | $6.71B | $7.86B | $8.50B | $16.07B | $12.17B | $13.12B | $14.20B | $14.34B |
| Revenue growth (YoY) | — | +97.1% | +90.7% | +59.1% | +21.0% | -2.9% | +209.2% | +52.7% | +34.0% | +45.5% | +18.4% | +20.8% | +14.3% | +17.2% | +8.1% | +89.1% | -24.3% | +7.8% | +8.3% | +1.0% |
| Cost of revenue | $22.74M | $227.99M | $923000.00 | $15.93M | $2.09M | $4.22M | $84.45M | $155.35M | $205.02M | $392.71M | $299.69M | $397.06M | $434.10M | $782.20M | $1.36B | $2.72B | $1.71B | $883.70M | $1.97B | $2.10B |
| Gross profit | $40.71M | $125.02M | $237.53M | $363.33M | $456.98M | $441.61M | $1.29B | $1.95B | $2.61B | $3.71B | $4.56B | $5.48B | $6.28B | $7.08B | $7.14B | $13.35B | $10.47B | $12.23B | $12.23B | $12.24B |
| Gross margin | 64.2% | 100.0% | 99.6% | 95.8% | 99.5% | 99.1% | 93.9% | 92.6% | 92.7% | 90.4% | 93.8% | 93.2% | 93.5% | 90.1% | 84.0% | 83.1% | 86.0% | 93.3% | 86.1% | 85.4% |
| R&D | $122.12M | $190.13M | $278.02M | $384.51M | $489.25M | $529.51M | $625.55M | $859.95M | $1.27B | $1.62B | $2.05B | $2.08B | $2.19B | $3.04B | $2.50B | $2.62B | $3.06B | $4.44B | $5.23B | $5.85B |
| SG&A | $25.89M | $37.87M | $49.35M | $52.92M | $65.20M | $117.26M | $210.75M | $329.42M | $504.75M | $838.53M | $1.18B | $1.32B | $1.56B | $1.83B | $1.35B | $1.82B | $2.12B | $2.55B | $2.95B | $2.70B |
| Operating income | $-107.31M | $-114.45M | $-89.83M | $-74.10M | $-97.47M | $-205.16M | $457.71M | $760.03M | $838.43M | $1.25B | $1.33B | $2.08B | $2.53B | $2.21B | $3.58B | $8.95B | $5.39B | $4.05B | $3.99B | $3.58B |
| Operating margin | -169.1% | -91.5% | -37.7% | -19.5% | -21.2% | -46.0% | 33.2% | 36.1% | 29.7% | 30.5% | 27.4% | 35.4% | 37.8% | 28.1% | 42.1% | 55.7% | 44.2% | 30.9% | 28.1% | 24.9% |
| EBITDA | $-76.52M | $-82.07M | $-78.54M | $-55.37M | $-77.78M | $-174.08M | $494.65M | $801.23M | $891.12M | $1.33B | $1.44B | $2.23B | $2.68B | $2.42B | $4.10B | $9.67B | $5.26B | $4.05B | $5.32B | $5.82B |
| EBITDA margin | -120.6% | -65.6% | -32.9% | -14.6% | -16.9% | -39.0% | 35.9% | 38.1% | 31.6% | 32.3% | 29.5% | 37.9% | 40.0% | 30.8% | 48.3% | 60.2% | 43.2% | 30.9% | 37.4% | 40.6% |
| EBIT | $-91.11M | $-93.56M | $-89.83M | $-69.61M | $-97.47M | $-205.16M | $457.71M | $760.03M | $838.43M | $1.25B | $1.33B | $2.08B | $2.53B | $2.21B | $3.87B | $9.38B | $4.92B | $4.05B | $4.84B | $5.27B |
| Interest expense | $16.55M | $12.04M | $7.75M | $2.34M | $9.12M | $21.28M | $45.30M | $46.44M | $37.37M | $14.24M | $7.20M | $25.12M | $28.20M | $30.20M | $56.90M | $57.30M | $59.40M | $73.00M | $55.20M | $43.80M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-102.34M | $-105.60M | $-82.71M | $-67.83M | $-104.47M | $-221.76M | $750.27M | $424.36M | $348.07M | $636.06M | $895.52M | $1.20B | $2.44B | $2.12B | $3.51B | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| Net income growth (YoY) | — | -3.2% | +21.7% | +18.0% | -54.0% | -112.3% | +438.3% | -43.4% | -18.0% | +82.7% | +40.8% | +33.8% | +104.0% | -13.4% | +66.0% | +129.9% | -46.3% | -8.9% | +11.6% | +2.1% |
| Profit margin | -161.3% | -84.5% | -34.7% | -17.9% | -22.8% | -49.7% | 54.4% | 20.2% | 12.3% | 15.5% | 18.4% | 20.4% | 36.4% | 26.9% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |